CoChat

Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5

Open access
Li, Meiling, Kim, Yu-Mi, Koh, Jung Hee, Park, Jihyun, Kwon, H. Moo, Park, Jong-Hwan, Jin, Jingchun, Park, Youngjae, Kim, Donghyun, Kim, Wan-Uk · 2024 · Journal of Clinical Investigation

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Nuclear factor of activated T-cells 5 (NFAT5), an osmo-sensitive transcription factor, can be activated by isotonic stimuli, such as infection. It remains unclear, however, whether NFAT5 is required for damage-associated molecular pattern-triggered (DAMP-triggered) inflammation and immunity. Here, we found that several DAMPs increased NFAT5 expression in macrophages. In particular, serum amyloid A (SAA), primarily generated by the liver, substantially upregulated NFAT5 expression and activity through TLR2/4-JNK signalling pathway. Moreover, the SAA-TLR2/4-NFAT5 axis promoted migration and chemotaxis of macrophages in an IL-6- and chemokine ligand 2-dependent (CCL2-dependent) manner in vitro. Intraarticular injection of SAA markedly accelerated macrophage infiltration and arthritis progression in mice. By contrast, genetic ablation of NFAT5 or TLR2/4 rescued the pathology induced by SAA, confirming the SAA-TLR2/4-NFAT5 axis in vivo. Myeloid-specific depletion of NFAT5 also attenuated SAA-accelerated arthritis. Of note, inflammatory arthritis in mice strikingly induced SAA overexpression in the liver. Conversely, forced overexpression of the SAA gene in the liver accelerated joint damage, indicating that the liver contributes to bolstering chronic inflammation at remote sites by secreting SAA. Collectively, this study underscores the importance of the SAA-TLR2/4-NFAT5 axis in innate immunity, suggesting that acute phase reactant SAA mediates mutual interactions between liver and joints and ultimately aggravates chronic arthritis by enhancing macrophage activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci167835

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SAA-induced upregulation of NFAT5 expression and activity in macrophages. (A and B) Western blot analysis of NFAT5 in (A) RAW 264.7 macrophages, (B) primary mouse macrophages (BMDMs, left; peritoneal macrophages, middle) and human peripheral CD14+ monocytes (right) after SAA (5 μg/mL) treatment. β-actin served as a loading control. Data are representative of at least 3 independent experiments. (C) Nfat5 mRNA expression levels in RAW264.7 cells and BMDMs after treatment with SAA (5 μg/mL). For qRT-PCR, Gapdh mRNA was used as an internal control. (D) Time course of NFAT5 localization in RAW 264.7 macrophages (n = 5) treated with SAA. NFAT5 expression was determined by immunoflorescent staining and is shown as fluorescence intensity. (E) Luciferase reporter assays for NFAT5-dependent promotor activity in RAW 264.7 macrophages treated with SAA for 24 hours after transduction of luciferase constructs (n = 3). (F) In vivo analysis of NFAT5 reporter activity in mice implanted with matrigel containing RAW 264.7 macrophages transfected with NFAT5-RFP reporter. SAA (10 μg/mL) was premixed (top) with matrigel or injected s.c. into the mice (middle and bottom). Representative images are shown. (G and H) Triple immunofluorescence staining of RA synovium for CD14 (red), NFAT5 (white), and SAA (green). Nuclei were counterstained with DAPI (blue). Scale bars: 10 μm. Data representative of more than 3 patients with RA is shown (G). Significance of colocalization was assessed by Pearson’s correlation coefficient analysis (H). (I) SAA concentrations in synovial fluids (SF) of patients with RA (n = 60) and OA (n = 33), as determined by ELISA. (J) Flow cytometry analysis of NFAT5 expression in CD14+ cells freshly isolated from the SF of patients with RA (n = 6) and OA (n = 3). (K and L) Correlation between SAA concentrations measured by ELISA and NFAT5 expression levels in CD14+ cells by flow cytometry (K) or qRT-PCR (L) in SF of patients with RA. Data in (C–E, and J) are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 1-way ANOVA with Dunn’s multiple comparisons test (C), Friedman’s test with Dunn’s multiple comparisons test (D), Kruskal-Wallis test with Dunn’s multiple comparisons test (E), Mann Whitney U test (I), unpaired t test (J), and Pearson correlation test (K and L).
Figure 1 SAA-induced upregulation of NFAT5 expression and activity in macrophages. (A and B) Western blot analysis of NFAT5 in (A) RAW 264.7 macrophages, (B) primary mouse macrophages (BMDMs, left; peritoneal macrophages, middle) and human peripheral CD14+ monocytes (right) after SAA (5 μg/mL) treatment. β-actin served as a loading control. Data are representative of at least 3 independent experiments. (C) Nfat5 mRNA expression levels in RAW264.7 cells and BMDMs after treatment with SAA (5 μg/mL). For qRT-PCR, Gapdh mRNA was used as an internal control. (D) Time course of NFAT5 localization in RAW 264.7 macrophages (n = 5) treated with SAA. NFAT5 expression was determined by immunoflorescent staining and is shown as fluorescence intensity. (E) Luciferase reporter assays for NFAT5-dependent promotor activity in RAW 264.7 macrophages treated with SAA for 24 hours after transduction of luciferase constructs (n = 3). (F) In vivo analysis of NFAT5 reporter activity in mice implanted with matrigel containing RAW 264.7 macrophages transfected with NFAT5-RFP reporter. SAA (10 μg/mL) was premixed (top) with matrigel or injected s.c. into the mice (middle and bottom). Representative images are shown. (G and H) Triple immunofluorescence staining of RA synovium for CD14 (red), NFAT5 (white), and SAA (green). Nuclei were counterstained with DAPI (blue). Scale bars: 10 μm. Data representative of more than 3 patients with RA is shown (G). Significance of colocalization was assessed by Pearson’s correlation coefficient analysis (H). (I) SAA concentrations in synovial fluids (SF) of patients with RA (n = 60) and OA (n = 33), as determined by ELISA. (J) Flow cytometry analysis of NFAT5 expression in CD14+ cells freshly isolated from the SF of patients with RA (n = 6) and OA (n = 3). (K and L) Correlation between SAA concentrations measured by ELISA and NFAT5 expression levels in CD14+ cells by flow cytometry (K) or qRT-PCR (L) in SF of patients with RA. Data in (C–E, and J) are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 1-way ANOVA with Dunn’s multiple comparisons test (C), Friedman’s test with Dunn’s multiple comparisons test (D), Kruskal-Wallis test with Dunn’s multiple comparisons test (E), Mann Whitney U test (I), unpaired t test (J), and Pearson correlation test (K and L).CC BY · PubMed Central
Figure 2 SAA upregulation of NFAT5 expression via TLR2/4-JNK pathway in macrophages. (A and B) Western blot analysis for NFAT5 expression in RAW 264.7 macrophages treated with TAK-242 (TAK) or oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) in the presence of SAA. (C) NFAT5 expression in SAA-treated BMDMs of WT, TLR4 KO (Tlr4–/–) and TLR2/4 double KO (Tlr2/4–/–) mice. (D and E) Increase in phospho-p38 (p-p38), phospho-ERK (p-ERK1/2), phospho-JNK1/2 (p-JNK1/2), and phospho-AKT (p-AKT) levels by SAA (5 μg/mL) in RAW 264.7 macrophages (D) and mouse BMDMs (E), as determined by Western blot. (F) NFAT5 expression in RAW 264.7 macrophages pretreated with SB203580 (SB, 15 [SB15] and 30 μM [SB30]), PD98059 (PD, 30 μM), SP600125 (SP, 10 μM), LY294002 (LY, 10 μM), Wortmannin (Wort, 10 μM), and allopurinol (Allo, 1 mM) for 1 hour. (G and H) SP600125 inhibition of NFAT5 expression in RAW 264.7 macrophages (G) and mouse BMDMs (H) stimulated with SAA. (I) Reduction of NFAT5 expression in RAW 264.7 macrophages by Jnk1/2 siRNA. Cells were transfected with control or Jnk1/2 siRNA for 24 hours and then treated with SAA (5 μg/mL) for 8 hours. Expression of NFAT5 and total JNK1/2 was measured by Western blot analysis. (J) Decrease in p-JNK1/2 expression by Tlr2/4 deficiency. BMDMs of WT, Tlr2–/–, Tlr4–/–, Tlr2/4–/– mice were activated with SAA for the indicated times. Total JNK1/2 and p-JNK1/2 expressions were determined by Western blotting. Data are representative of more than 3 independent experiments with similar results. In experiments for A, B, C, F, G, and H, the cells were stimulated with 5 μg/mL of SAA for 24 hours.
Figure 2 SAA upregulation of NFAT5 expression via TLR2/4-JNK pathway in macrophages. (A and B) Western blot analysis for NFAT5 expression in RAW 264.7 macrophages treated with TAK-242 (TAK) or oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) in the presence of SAA. (C) NFAT5 expression in SAA-treated BMDMs of WT, TLR4 KO (Tlr4–/–) and TLR2/4 double KO (Tlr2/4–/–) mice. (D and E) Increase in phospho-p38 (p-p38), phospho-ERK (p-ERK1/2), phospho-JNK1/2 (p-JNK1/2), and phospho-AKT (p-AKT) levels by SAA (5 μg/mL) in RAW 264.7 macrophages (D) and mouse BMDMs (E), as determined by Western blot. (F) NFAT5 expression in RAW 264.7 macrophages pretreated with SB203580 (SB, 15 [SB15] and 30 μM [SB30]), PD98059 (PD, 30 μM), SP600125 (SP, 10 μM), LY294002 (LY, 10 μM), Wortmannin (Wort, 10 μM), and allopurinol (Allo, 1 mM) for 1 hour. (G and H) SP600125 inhibition of NFAT5 expression in RAW 264.7 macrophages (G) and mouse BMDMs (H) stimulated with SAA. (I) Reduction of NFAT5 expression in RAW 264.7 macrophages by Jnk1/2 siRNA. Cells were transfected with control or Jnk1/2 siRNA for 24 hours and then treated with SAA (5 μg/mL) for 8 hours. Expression of NFAT5 and total JNK1/2 was measured by Western blot analysis. (J) Decrease in p-JNK1/2 expression by Tlr2/4 deficiency. BMDMs of WT, Tlr2–/–, Tlr4–/–, Tlr2/4–/– mice were activated with SAA for the indicated times. Total JNK1/2 and p-JNK1/2 expressions were determined by Western blotting. Data are representative of more than 3 independent experiments with similar results. In experiments for A, B, C, F, G, and H, the cells were stimulated with 5 μg/mL of SAA for 24 hours.CC BY · PubMed Central
Figure 3 Requirement of NFAT5 for SAA-induced macrophage migration. (A and B) Immunocytochemical analysis of F-actin (red) in RAW 264.7 macrophages transfected with NFAT5 shRNA (A) and peritoneal macrophages of Nfat5+/– mice (B), stimulated with SAA (2.5 μg/mL) for 2.5 hours. Nuclei were counterstained with DAPI (blue). Arrows indicate filopodia and lamellipodia. Scale bars: 10 μm. (C) Decrease in SAA-induced wound migration of RAW 264.7 macrophages by NFAT5 knockdown (KD). Scale bar: 400 μm. (D and E) Decrease in transwell migration of NFAT5 KD RAW 264.7 macrophages (D) and Nfat5+/– BMDM (E) stimulated with SAA (5 μg/mL). Scale bars: 500 μm. (F) Macrophage migration in SAA-stimulated air pouch in vivo. After air pouches were established in BALB/c mice, the mice were subjected to i.v. injection of NFAT5 KD or control RAW 264.7 cells (1 × 105) labeled with GFP. After 48 hours, the ratio of GFP+ cells migrating to the air pouch cavity containing SAA (20 μg/mL) were evaluated by flow cytometry. (G and H) Chemotactic migration of macrophages to conditioned media. Conditioned media (SAASup) were harvested from Nfat5-deficient (KD) or -sufficient RAW 264.7 macrophages (G) and BMDM (H) 24 hours after stimulation with SAA (5 μg/mL). Scale bars: 100 μm. Data represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Brown–Forsythe and Welch’s ANOVA (C, G, and H), 1-way ANOVA test (D and E), and Kruskal-Wallis test (F). Comparison of numerical data between groups were performed using the unpaired t test, Welch’s t test, or Mann-Whitney U test.
Figure 3 Requirement of NFAT5 for SAA-induced macrophage migration. (A and B) Immunocytochemical analysis of F-actin (red) in RAW 264.7 macrophages transfected with NFAT5 shRNA (A) and peritoneal macrophages of Nfat5+/– mice (B), stimulated with SAA (2.5 μg/mL) for 2.5 hours. Nuclei were counterstained with DAPI (blue). Arrows indicate filopodia and lamellipodia. Scale bars: 10 μm. (C) Decrease in SAA-induced wound migration of RAW 264.7 macrophages by NFAT5 knockdown (KD). Scale bar: 400 μm. (D and E) Decrease in transwell migration of NFAT5 KD RAW 264.7 macrophages (D) and Nfat5+/– BMDM (E) stimulated with SAA (5 μg/mL). Scale bars: 500 μm. (F) Macrophage migration in SAA-stimulated air pouch in vivo. After air pouches were established in BALB/c mice, the mice were subjected to i.v. injection of NFAT5 KD or control RAW 264.7 cells (1 × 105) labeled with GFP. After 48 hours, the ratio of GFP+ cells migrating to the air pouch cavity containing SAA (20 μg/mL) were evaluated by flow cytometry. (G and H) Chemotactic migration of macrophages to conditioned media. Conditioned media (SAASup) were harvested from Nfat5-deficient (KD) or -sufficient RAW 264.7 macrophages (G) and BMDM (H) 24 hours after stimulation with SAA (5 μg/mL). Scale bars: 100 μm. Data represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Brown–Forsythe and Welch’s ANOVA (C, G, and H), 1-way ANOVA test (D and E), and Kruskal-Wallis test (F). Comparison of numerical data between groups were performed using the unpaired t test, Welch’s t test, or Mann-Whitney U test.CC BY · PubMed Central
Figure 4 CCL2 and IL-6 reversal of macrophage migration repressed by Nfat5 deficiency. (A and B) Reduced IL-6 and CCL2 production by NFAT5 KD RAW 264.7 macrophages and Nfat5+/– BMDM, as determined by ELISA. The cells were stimulated with SAA for 24 hours. IL-6 and CCL2 concentrations in the culture supernatants were determined by ELISA. (C) Decrease in SAA-stimulated CCL2 promoter activity by the knockdown of NFAT5. NFAT5 KD or control RAW 264.7 macrophages (1 × 105) were transfected with CCL2 reporter plasmid (250 ng/well), and the transfected cells were then treated with the indicated concentrations of SAA for 18 hours. The CCL2 promoter activity was determined by luciferase assay. (D and E) Recovery effect of CCL2 and IL-6 on the decrease in macrophage migration by Nfat5 deficiency. In the same experimental conditions as A and B, recombinant CCL2 (10 ng/mL) or IL-6 (10 ng/mL) were added to NFAT5 KD RAW 264.7 cells (D) and Nfat5+/– BMDM (E). After 8 hours, the cell migration was determined by Boyden chamber assay. (F and G) Inhibition of macrophage migration by neutralizing Ab to CCL2 or IL-6. Anti-CCL2 Ab (1 μg/mL) or anti-IL-6 Ab (1 μg/mL) was mixed for 1 hour with the conditioned media of RAW264.7 cells (F) and BMDM (G), which were stimulated with SAA for 24 hours. Macrophage migration was assessed in a Boyden chamber 8 hours after the treatment of conditioned media in the absence or presence of the blocking Abs. Scale bars: 150 μm. Data represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Brown–Forsythe and Welch’s ANOVA (A and E), 1-way ANOVA test (D, F, and G), and Kruskal-Wallis test (B). Comparison of numerical data between groups were performed using the unpaired t test, Welch’s t test, Mann-Whitney U test or Tukey’s multiple comparisons test.
Figure 4 CCL2 and IL-6 reversal of macrophage migration repressed by Nfat5 deficiency. (A and B) Reduced IL-6 and CCL2 production by NFAT5 KD RAW 264.7 macrophages and Nfat5+/– BMDM, as determined by ELISA. The cells were stimulated with SAA for 24 hours. IL-6 and CCL2 concentrations in the culture supernatants were determined by ELISA. (C) Decrease in SAA-stimulated CCL2 promoter activity by the knockdown of NFAT5. NFAT5 KD or control RAW 264.7 macrophages (1 × 105) were transfected with CCL2 reporter plasmid (250 ng/well), and the transfected cells were then treated with the indicated concentrations of SAA for 18 hours. The CCL2 promoter activity was determined by luciferase assay. (D and E) Recovery effect of CCL2 and IL-6 on the decrease in macrophage migration by Nfat5 deficiency. In the same experimental conditions as A and B, recombinant CCL2 (10 ng/mL) or IL-6 (10 ng/mL) were added to NFAT5 KD RAW 264.7 cells (D) and Nfat5+/– BMDM (E). After 8 hours, the cell migration was determined by Boyden chamber assay. (F and G) Inhibition of macrophage migration by neutralizing Ab to CCL2 or IL-6. Anti-CCL2 Ab (1 μg/mL) or anti-IL-6 Ab (1 μg/mL) was mixed for 1 hour with the conditioned media of RAW264.7 cells (F) and BMDM (G), which were stimulated with SAA for 24 hours. Macrophage migration was assessed in a Boyden chamber 8 hours after the treatment of conditioned media in the absence or presence of the blocking Abs. Scale bars: 150 μm. Data represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Brown–Forsythe and Welch’s ANOVA (A and E), 1-way ANOVA test (D, F, and G), and Kruskal-Wallis test (B). Comparison of numerical data between groups were performed using the unpaired t test, Welch’s t test, Mann-Whitney U test or Tukey’s multiple comparisons test.CC BY · PubMed Central
Figure 5 Aggravation of suboptimal form of IL-1β–induced arthritis by SAA-TLR2/4-NFAT5 axis. SAA-accelerated arthritis in mice was generated by injecting SAA (5 μg × 1) in the affected joint of mice with a suboptimal form of IL-1β–induced arthritis, which was induced by injection of mBSA (200 μg × 1) and/or IL-1β (250 ng × 2) (See Supplemental Figure 8A). Arthritis severity was scored 7 days after SAA injection on a scale of 0 to 3 depending on the extent of inflammatory cell infiltration, synovial hyperplasia, and bone destruction. (A and B) Increases in the progression of chronic arthritis and infiltration of macrophages/neutrophils by intra-articular injection of SAA. The bar graphs represent mean ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001 by Mann Whitney U test for inflammatory cell infiltration and synovial hyperplasia in (A), unpaired t test for bone destruction in (A) and F4/80 in (B), and Welch’s t test for NIMP-R14 in (B). (C and D) Amelioration of SAA-accelerated arthritis and decrement of inflammatory cell (F4/80+ and NIMP-R14+ cells) infiltration by Nfat5 haploinsufficiency. The bar graphs represent mean ± SD. **P < 0.01 and ****P < 0.0001 by Mann Whitney U test for (C) and unpaired t test for (D). (E and F) Decrease in arthritis severity and inflammatory cell infiltration by specific KO of myeloid Nfat5. LysM-Cre;Nfat5fl/fl conditional KO mice were generated and subjected to SAA-accelerated arthritis. Nfat5fl/fl mice were used as controls. The bar graphs indicate mean ± SD. *P < 0.05 and **P < 0.01 by Mann Whitney U test. (G and H) Suppressive effect of Tlr2/4 KO on severity of SAA-accelerated arthritis and on infiltration of F4/80+ and NIMP-R14+ cells in the affected joints. The bar graphs indicate mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 by Mann Whitney U test for (G) and NIMP-R14 in (H), and unpaired t test for F4/80 in (H). Scale bars: 1 mm for H&E staining in A, C, E, and G. Scale bars for IHC staining of F4/80+ and NIMP-R14+ cells in B, D, F, and H: 500 μm for low magnification (left) and 50 μm for high magnification (right). Data in A, C, E, and G are representative of 2 independent experiments. Black arrowheads indicate F4/80+ macrophages or NIMP-R14+ neutrophils that have infiltrated into the synovium (B, D, F, and H).
Figure 5 Aggravation of suboptimal form of IL-1β–induced arthritis by SAA-TLR2/4-NFAT5 axis. SAA-accelerated arthritis in mice was generated by injecting SAA (5 μg × 1) in the affected joint of mice with a suboptimal form of IL-1β–induced arthritis, which was induced by injection of mBSA (200 μg × 1) and/or IL-1β (250 ng × 2) (See Supplemental Figure 8A). Arthritis severity was scored 7 days after SAA injection on a scale of 0 to 3 depending on the extent of inflammatory cell infiltration, synovial hyperplasia, and bone destruction. (A and B) Increases in the progression of chronic arthritis and infiltration of macrophages/neutrophils by intra-articular injection of SAA. The bar graphs represent mean ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001 by Mann Whitney U test for inflammatory cell infiltration and synovial hyperplasia in (A), unpaired t test for bone destruction in (A) and F4/80 in (B), and Welch’s t test for NIMP-R14 in (B). (C and D) Amelioration of SAA-accelerated arthritis and decrement of inflammatory cell (F4/80+ and NIMP-R14+ cells) infiltration by Nfat5 haploinsufficiency. The bar graphs represent mean ± SD. **P < 0.01 and ****P < 0.0001 by Mann Whitney U test for (C) and unpaired t test for (D). (E and F) Decrease in arthritis severity and inflammatory cell infiltration by specific KO of myeloid Nfat5. LysM-Cre;Nfat5fl/fl conditional KO mice were generated and subjected to SAA-accelerated arthritis. Nfat5fl/fl mice were used as controls. The bar graphs indicate mean ± SD. *P < 0.05 and **P < 0.01 by Mann Whitney U test. (G and H) Suppressive effect of Tlr2/4 KO on severity of SAA-accelerated arthritis and on infiltration of F4/80+ and NIMP-R14+ cells in the affected joints. The bar graphs indicate mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 by Mann Whitney U test for (G) and NIMP-R14 in (H), and unpaired t test for F4/80 in (H). Scale bars: 1 mm for H&E staining in A, C, E, and G. Scale bars for IHC staining of F4/80+ and NIMP-R14+ cells in B, D, F, and H: 500 μm for low magnification (left) and 50 μm for high magnification (right). Data in A, C, E, and G are representative of 2 independent experiments. Black arrowheads indicate F4/80+ macrophages or NIMP-R14+ neutrophils that have infiltrated into the synovium (B, D, F, and H).CC BY · PubMed Central
Figure 6 IL-1β–induced arthritis progresses to rheumatoid pathology by repeated challenges with SAA, whereas it is blocked by anti-SAA Ab. (A) SAA-accelerated arthritis was induced as in Supplemental Figure 8A. After 1 week, SAA (5 μg) or vehicle alone was additionally injected into the affected joint once a week for a total of 3 times. At day 28, arthritis severity was scored on a scale of 0 to 3, depending on the extent of inflammatory cell infiltration, synovial hyperplasia, and bone destruction. The bar graph represents mean ± SD. **P < 0.01 by Mann Whitney U test. (B) The joint pathology showing resolution of arthritis in mice singly injected with SAA versus ‘pannus formation’ (arrows) in addition to a more severe bony erosion and invasion (arrowheads) in mice receiving multiple injections of SAA. The bar graph represents mean ± SD of pannus formation score. ***P < 0.001 by Mann Whitney U test. (C) The degree of angiogenesis assessed by immunostaining for vWF using anti-vWF Ab. The bar graph represents mean ± SD of the stained area (mm2). **P < 0.01 by unpaired t test. (D) Toluidine blue stain for cartilage damage of the affected (knee) joint of mice with single versus multiple SAA injection. The bar graph indicates mean ± SD. ****P < 0.0001 by unpaired t test. (E) Amelioration of IL-1β-induced arthritis by anti-SAA Ab. Neutralizing Ab to SAA (1mg/kg) was i.p. injected on days 1 and 2 into the mice with a standard form of IL-1β–induced arthritis (IL-1β: 250 ng × 3, no SAA injection). The same concentration of isotype control IgG was used as a control. At day 7, arthritis severity was evaluated. The bar graph represents mean ± SD. *P < 0.05 and **P < 0.01 by Mann Whitney U test. Data in A and E are representative of 2 independent experiments.
Figure 6 IL-1β–induced arthritis progresses to rheumatoid pathology by repeated challenges with SAA, whereas it is blocked by anti-SAA Ab. (A) SAA-accelerated arthritis was induced as in Supplemental Figure 8A. After 1 week, SAA (5 μg) or vehicle alone was additionally injected into the affected joint once a week for a total of 3 times. At day 28, arthritis severity was scored on a scale of 0 to 3, depending on the extent of inflammatory cell infiltration, synovial hyperplasia, and bone destruction. The bar graph represents mean ± SD. **P < 0.01 by Mann Whitney U test. (B) The joint pathology showing resolution of arthritis in mice singly injected with SAA versus ‘pannus formation’ (arrows) in addition to a more severe bony erosion and invasion (arrowheads) in mice receiving multiple injections of SAA. The bar graph represents mean ± SD of pannus formation score. ***P < 0.001 by Mann Whitney U test. (C) The degree of angiogenesis assessed by immunostaining for vWF using anti-vWF Ab. The bar graph represents mean ± SD of the stained area (mm2). **P < 0.01 by unpaired t test. (D) Toluidine blue stain for cartilage damage of the affected (knee) joint of mice with single versus multiple SAA injection. The bar graph indicates mean ± SD. ****P < 0.0001 by unpaired t test. (E) Amelioration of IL-1β-induced arthritis by anti-SAA Ab. Neutralizing Ab to SAA (1mg/kg) was i.p. injected on days 1 and 2 into the mice with a standard form of IL-1β–induced arthritis (IL-1β: 250 ng × 3, no SAA injection). The same concentration of isotype control IgG was used as a control. At day 7, arthritis severity was evaluated. The bar graph represents mean ± SD. *P < 0.05 and **P < 0.01 by Mann Whitney U test. Data in A and E are representative of 2 independent experiments.CC BY · PubMed Central
Figure 7 CCL2 is responsible for arthritis progression as a target of the SAA/NFAT5 axis. (A–C) Quantitation by IHC staining of CCL2 expression in the affected joints of WT (A), Nfat5+/– (B), and LysM-Cre;Nfat5fl/fl mice (C) with SAA-accelerated arthritis (See Supplemental Figure 8A), compared with their respective controls. Data represent mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Mann Whitney U test (A) and unpaired t test (B and C). Scale bars: 500 μm for low magnification (left panel) and 50 μm for high magnification (right panel). (D) Immunofluorescence colocalization for F4/80 (green) with CCL2 (red) in the affected joints of Nfat5fl/fl versus LysM-Cre; Nfat5fl/fl mice with SAA-accelerated arthritis. Nuclei were counterstained with DAPI (blue). The bar graphs represent mean ± SD. *P < 0.05 by Mann Whitney U test for immunostaining of F4/80+ cells and Kruskal-Wallis test with post hoc Mann-Whitney U test for immunostaining of CCL2+ cells. Scale bars: 20 μm. (E) Histological severity of the affected joints of LysM-Cre;Nfat5fl/fl mice injected intraarticularly with CCL2 (2 μg × 3) versus vehicle alone. The Nfat5fl/fl mice with SAA-accelerated arthritis were used as a positive control. Mean histological severity is shown on the right. Data are mean ± SD. *P < 0.05 and **P < 0.01 by Kruskal-Wallis test with a Dunn’s multiple comparisons test. Scale bars: 500 μm. Data are representative of 2 independent experiments. (F) Quantitation of F4/80+ macrophage and NIMP-R14+ neutrophil infiltration in the affected joints between LysM-Cre;Nfat5fl/fl mice injected intraarticularly with CCL2 (2 μg × 3) and those with vehicle alone. The bar graph indicates mean ± SD. *P < 0.05 and **P < 0.01 by 1-way ANOVA with Tukey’s multiple comparisons test for immunostaining of F4/80 and Kruskal-Wallis test with a Dunn’s multiple comparisons test for immunostaining of NIMP-R14. Scale bars: 50 μm.
Figure 7 CCL2 is responsible for arthritis progression as a target of the SAA/NFAT5 axis. (A–C) Quantitation by IHC staining of CCL2 expression in the affected joints of WT (A), Nfat5+/– (B), and LysM-Cre;Nfat5fl/fl mice (C) with SAA-accelerated arthritis (See Supplemental Figure 8A), compared with their respective controls. Data represent mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Mann Whitney U test (A) and unpaired t test (B and C). Scale bars: 500 μm for low magnification (left panel) and 50 μm for high magnification (right panel). (D) Immunofluorescence colocalization for F4/80 (green) with CCL2 (red) in the affected joints of Nfat5fl/fl versus LysM-Cre; Nfat5fl/fl mice with SAA-accelerated arthritis. Nuclei were counterstained with DAPI (blue). The bar graphs represent mean ± SD. *P < 0.05 by Mann Whitney U test for immunostaining of F4/80+ cells and Kruskal-Wallis test with post hoc Mann-Whitney U test for immunostaining of CCL2+ cells. Scale bars: 20 μm. (E) Histological severity of the affected joints of LysM-Cre;Nfat5fl/fl mice injected intraarticularly with CCL2 (2 μg × 3) versus vehicle alone. The Nfat5fl/fl mice with SAA-accelerated arthritis were used as a positive control. Mean histological severity is shown on the right. Data are mean ± SD. *P < 0.05 and **P < 0.01 by Kruskal-Wallis test with a Dunn’s multiple comparisons test. Scale bars: 500 μm. Data are representative of 2 independent experiments. (F) Quantitation of F4/80+ macrophage and NIMP-R14+ neutrophil infiltration in the affected joints between LysM-Cre;Nfat5fl/fl mice injected intraarticularly with CCL2 (2 μg × 3) and those with vehicle alone. The bar graph indicates mean ± SD. *P < 0.05 and **P < 0.01 by 1-way ANOVA with Tukey’s multiple comparisons test for immunostaining of F4/80 and Kruskal-Wallis test with a Dunn’s multiple comparisons test for immunostaining of NIMP-R14. Scale bars: 50 μm.CC BY · PubMed Central
Figure 8 Liver is one of the major sources of SAA production in inflammatory arthritis. (A) Levels of SAA in paired sera and synovial fluids isolated simultaneously from patients with RA (n = 25), as determined by ELISA. Data are mean ± SD. ****P < 0.0001 by Wilcoxon matched pairs signed rank test. (B and C) qPCR analysis of mSaa1, mSaa2, and mSaa3 mRNA expression levels in the liver and joint tissues of mice injected i.p. with 10 mg/kg of LPS (B) or in those of mice injected with mBSA (200 μg, 1 × on day 0) and/or IL-1β (250 ng, 3 × on days 0, 1, and 2) (C). Data are mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001by Kruskal-Wallis test for mSaa1 and mSaa2 (B), Brown–Forsythe and Welch’s ANOVA test for mSaa3 (B), 2-way ANOVA test for mSaa1 and mSaa3 (C), and Friedman’s test for mSaa2 (C). Comparison of numerical data between groups were performed using the unpaired t test, Welch’s t test, or Mann-Whitney U test. Data are representative of 2 independent experiments. (D) SAA production from cultured hepatocytes and synoviocytes. Hepatocytes (1 × 105/well) and fibroblast-like synoviocytes (5 × 104/well), isolated from C57BL/6 mice, were stimulated with LPS (10 ng/mL), IL-6 (10 ng/mL), and IL-1β (10 ng/mL) for the indicated times. The concentration of SAA in the culture supernatants was determined by ELISA. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test.
Figure 8 Liver is one of the major sources of SAA production in inflammatory arthritis. (A) Levels of SAA in paired sera and synovial fluids isolated simultaneously from patients with RA (n = 25), as determined by ELISA. Data are mean ± SD. ****P < 0.0001 by Wilcoxon matched pairs signed rank test. (B and C) qPCR analysis of mSaa1, mSaa2, and mSaa3 mRNA expression levels in the liver and joint tissues of mice injected i.p. with 10 mg/kg of LPS (B) or in those of mice injected with mBSA (200 μg, 1 × on day 0) and/or IL-1β (250 ng, 3 × on days 0, 1, and 2) (C). Data are mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001by Kruskal-Wallis test for mSaa1 and mSaa2 (B), Brown–Forsythe and Welch’s ANOVA test for mSaa3 (B), 2-way ANOVA test for mSaa1 and mSaa3 (C), and Friedman’s test for mSaa2 (C). Comparison of numerical data between groups were performed using the unpaired t test, Welch’s t test, or Mann-Whitney U test. Data are representative of 2 independent experiments. (D) SAA production from cultured hepatocytes and synoviocytes. Hepatocytes (1 × 105/well) and fibroblast-like synoviocytes (5 × 104/well), isolated from C57BL/6 mice, were stimulated with LPS (10 ng/mL), IL-6 (10 ng/mL), and IL-1β (10 ng/mL) for the indicated times. The concentration of SAA in the culture supernatants was determined by ELISA. Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test.CC BY · PubMed Central
Figure 9 Accelerated chronic arthritis by forced overexpression of SAA in the liver. (A) In vivo luciferase imaging of mouse whole body with a suboptimal form of IL-1β-induced arthritis before and after i.v. injection of Ad-mSaa1 and Ad-Con (See Supplemental Figure 8C). Mean (± SD) bioluminescence signal intensity (p/s/cm2/sr) in the liver at different time points is shown on the right. (B) SAA1/2 levels in the sera of mice with IL-1β–induced arthritis before and after injecting Ad-mSaa1 versus Ad-Con, as determined by ELISA. Data are mean ± SD. ****P < 0.0001 by 2-way ANOVA with Šidák’s multiple comparisons test. (C) Deterioration of chronic arthritis by overexpression of Saa1 in the livers of mice. 7 days after injection of Ad-mSaa1 and Ad-Con, arthritis severity was histologically assessed. The bar graph represents mean ± SD. **P < 0.01 by unpaired t test. Scale bars: 500 μm (D) Quantitation of F4/80+ macrophage infiltration and immunofluorescence colocalization for CCL2 (red), NFAT5 (green), and F4/80 (white) in the affected joints of mice with forced overexpression of Saa1 in the liver compared with control mice without Saa1 overexpression. The bar graphs indicate mean ± SD. *P < 0.05 and **P < 0.01 by Welch’s t test for NFAT5+, F4/80+, and CCL2+ cells, and by 1-way ANOVA with Tukey’s multiple comparisons test for F4/80+ CCL2+ (double positive) cells. Scale bars: 20 μm. Data are representative of 2 independent experiments.
Figure 9 Accelerated chronic arthritis by forced overexpression of SAA in the liver. (A) In vivo luciferase imaging of mouse whole body with a suboptimal form of IL-1β-induced arthritis before and after i.v. injection of Ad-mSaa1 and Ad-Con (See Supplemental Figure 8C). Mean (± SD) bioluminescence signal intensity (p/s/cm2/sr) in the liver at different time points is shown on the right. (B) SAA1/2 levels in the sera of mice with IL-1β–induced arthritis before and after injecting Ad-mSaa1 versus Ad-Con, as determined by ELISA. Data are mean ± SD. ****P < 0.0001 by 2-way ANOVA with Šidák’s multiple comparisons test. (C) Deterioration of chronic arthritis by overexpression of Saa1 in the livers of mice. 7 days after injection of Ad-mSaa1 and Ad-Con, arthritis severity was histologically assessed. The bar graph represents mean ± SD. **P < 0.01 by unpaired t test. Scale bars: 500 μm (D) Quantitation of F4/80+ macrophage infiltration and immunofluorescence colocalization for CCL2 (red), NFAT5 (green), and F4/80 (white) in the affected joints of mice with forced overexpression of Saa1 in the liver compared with control mice without Saa1 overexpression. The bar graphs indicate mean ± SD. *P < 0.05 and **P < 0.01 by Welch’s t test for NFAT5+, F4/80+, and CCL2+ cells, and by 1-way ANOVA with Tukey’s multiple comparisons test for F4/80+ CCL2+ (double positive) cells. Scale bars: 20 μm. Data are representative of 2 independent experiments.CC BY · PubMed Central
Figure 10 Serial monitoring of serum SAA levels before and after treatment with antirheumatic drugs in patients with RA. (A) Correlation between SAA level and disease activity of RA. Serum SAA levels were measured by ELISA both before and 6 months after treatment with antirheumatic drugs, including TNFi, Tocilizumab, an anti-IL-6 receptor Ab, JAKi, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (See Supplemental Table 1 for more details). At the time of blood sampling, the DAS28, which represents RA activity, was assessed. The correlation analysis was performed using the Spearman test. (B) The ΔSAA from baseline to 6-month follow-up according to the treatment response. Good, moderate, and no response were defined according to EULAR response criteria. ****P < 0.0001 by Wilcoxon matched pairs signed rank test. (C) Comparison of ΔSAA levels depending on the kinds of antirheumatic drugs, including TNFi, Tocilizumab, JAKi, and csDMARDs. Data are mean ± SD. *P < 0.05 and **P < 0.01, by Kruskal-Wallis test with Dunn’s multiple comparisons test. (D) Positive correlations of ΔSAA with ΔCRP, ΔESR, and ΔDAS28. The correlation analysis was performed using the Spearman test.
Figure 10 Serial monitoring of serum SAA levels before and after treatment with antirheumatic drugs in patients with RA. (A) Correlation between SAA level and disease activity of RA. Serum SAA levels were measured by ELISA both before and 6 months after treatment with antirheumatic drugs, including TNFi, Tocilizumab, an anti-IL-6 receptor Ab, JAKi, and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (See Supplemental Table 1 for more details). At the time of blood sampling, the DAS28, which represents RA activity, was assessed. The correlation analysis was performed using the Spearman test. (B) The ΔSAA from baseline to 6-month follow-up according to the treatment response. Good, moderate, and no response were defined according to EULAR response criteria. ****P < 0.0001 by Wilcoxon matched pairs signed rank test. (C) Comparison of ΔSAA levels depending on the kinds of antirheumatic drugs, including TNFi, Tocilizumab, JAKi, and csDMARDs. Data are mean ± SD. *P < 0.05 and **P < 0.01, by Kruskal-Wallis test with Dunn’s multiple comparisons test. (D) Positive correlations of ΔSAA with ΔCRP, ΔESR, and ΔDAS28. The correlation analysis was performed using the Spearman test.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. 10.1002/1529-0131(200101)44:1<111::AID-ANR15>3.0.CO;2-1 · doi:10.1002/1529-0131(200101)44:1<111::aid-anr15>3.0.co;2-1

Cited by

See all 25

Metadata

Authors
Li, M., Kim, Y.-M., Koh, J. H., Park, J., Kwon, H. M., Park, J.-H., Jin, J., Park, Y., Kim, D., & Kim, W.-U.
Affiliations
  • Catholic University of Korea (KR)
  • The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
  • Chonnam National University (KR)
  • Ulsan National Institute of Science and Technology (KR)
  • Yanbian University Hospital (CN)
Corresponding author
Kim, Wan-Uk
Venue
Journal of Clinical Investigation
Published
2024-03-01
Volume
134
Issue
5
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4392282850
Cited by
25
References
55
Citations by year
2026: 6 · 2025: 15 · 2024: 4
FWCI
4.16
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • The National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (2015R1A3A2032927, 2022R1A2C1010356)
  • The National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1I1A2069425)
  • The National Research Foundation of Korea (NRF) funded by the National Priority Research Center Program Grant (NRF-2021R1A6A1A03038865)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
serum amyloid A, NFAT5, synovial macrophages, chronic arthritis, TLR2/4, JNK signaling, damage-associated molecular patterns, macrophage migration, MCP-1, interleukin-6, innate immunity, osmotic stress, myeloid-specific knockout
MeSH terms
Serum Amyloid A Protein, Animals, Arthritis, Inflammation, Liver, Macrophage Activation, Transcription Factors, Toll-Like Receptor 2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5. https://app.cochat.ai/papers/10.1172/jci167835
The paper
Li, M., Kim, Y.-M., Koh, J. H., Park, J., Kwon, H. M., Park, J.-H., Jin, J., Park, Y., Kim, D., & Kim, W.-U. (2024). Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5. Journal of Clinical Investigation. https://doi.org/10.1172/jci167835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.